Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NuGen Medical Devices Inc ( (TSE:NGMD) ) has shared an update.
NuGen Medical Devices has filed a patent for a Ready-to-Fill COP/COC needle-free injection nozzle that functions like a prefilled syringe but without a needle, enabling high-pressure jet injection and aseptic fill-finish compatibility. The patented nozzle is the core of NuGen’s Prefilled Nozzle platform, which pairs prefilled nozzles with a reusable auto-injector designed to deliver fixed doses from multiple nozzle formats.
Developed in collaboration with Gerresheimer Medical Plastics, the system is aligned with existing prefilled syringe manufacturing lines, aiming to ease adoption for pharmaceutical partners and support complex biologics such as GLP‑1s and monoclonal antibodies. The platform promises ESG and safety benefits by reducing drug waste, enabling fast injections, and eliminating needle-stick risks, with pre-clinical samples targeted by end-2026 and a fixed-dose auto-injector launch planned for 2027, potentially strengthening NuGen’s competitive position in the expanding prefilled drug delivery market.
More about NuGen Medical Devices Inc
NuGen Medical Devices Inc. is a medical technology company specializing in needle-free drug delivery systems for subcutaneous administration. Its flagship InsuJet device targets diabetes care and is approved in 42 countries, positioning the company within the growing market for patient-friendly, injection-based therapies.
Average Trading Volume: 77,027
Technical Sentiment Signal: Sell
Current Market Cap: C$4.18M
Learn more about NGMD stock on TipRanks’ Stock Analysis page.